



FOR IMMEDIATE RELEASE

CONTACT: Please call RedPath's offices at
412-231-3600 or 800-495-9885
or email info@redpathip.com

**LYNN M. BRUSCO, Pittsburgh Life Sciences Greenhouse
412-770-1353**

**MARCH COMES IN LIKE A LION FOR REDPATH AS IT RAMPS UP
SALES, STAFFING AND OPERATIONS**
Organizational Expansion Follows Successful Financing Round

PITTSBURGH, PA – March 8, 2007 – On the heels of an influx of funding received late in 2006, RedPath Integrated Pathology, Inc., announced today it has hit the ground running in March with increased sales, staff and a new operating structure.

“We’ve continued an 18-month sales ramp, increasing revenues in 2006 by 230 percent as compared to 2005,” said RedPath Integrated Pathology, Inc. President and CEO Mary Del Brady. “In the first two months of 2007, our revenues are double what they were for the same period a year ago. We’re now providing molecular-based testing in more than half of the nation’s top cancer centers, and we are involved in research collaborations to develop new indications for RedPath’s platform technology. These collaborations are with MD Anderson, Columbia University and the University of Virginia Medical School.”

RedPath credited fourth quarter Series A financing for creating a significant opportunity to accelerate growth and scale company operations for its next level of expansion.

Brady said, “thanks to the efforts of RedPath’s core team and the results it’s achieved to date, the company was able to attract the funding needed to implement strategies for expanding its reach within the laboratory services sector and double the size of its workforce from 10 to 20 employees in the past five months.” She continued, “we anticipate the hiring an of additional eight staff members in sales and operations in 2007.”

(more)

As part of the company's retrenching for growth, Brady said the company made three key appointments to its senior management team:

Hal Walsh joined RedPath as the Vice President, Sales and Marketing. He brings more than 20 years of healthcare experience in in-vitro diagnostics, medical devices and laboratory services. In the last 15 years, Walsh has developed a number of new healthcare businesses including businesses focused on cancer diagnostics and outpatient surgery centers. Walsh joined RedPath from Quest Diagnostics, Inc. where he held a general management position and led a 400-person sales and operations team with a heavy emphasis on pathology services and molecular testing.

"I look forward to marketing *PathFinderTG*®, which dramatically changes the diagnosis and treatment planning of cancer patients," said Walsh. "RedPath's technology in drug discovery holds tremendous potential as the market moves towards personalized treatment of cancer patients."

Rina Wolf joined RedPath as the Vice President, Reimbursement and Payor Relations. Wolf has extensive experience in developing reimbursement strategies and obtaining payer coverage for leading edge cancer diagnostic companies such as Esoterix, Inc. (now LabCorp) and, most recently, Genomic Health, Inc. Wolf brings a wealth of experience, insight and relationships to this critical function.

"I've never seen such a vast and compelling body of evidence that clearly demonstrates the broad clinical value for the diagnosis and staging of suspected cancers, as does the *PathFinderTG* test," said Wolf.

Ernest Jacobs, M.D., joined RedPath as Vice President of Technical Operations. Jacobs, with 30 years of experience in medicine, technology transfer and systems engineering, has returned to western Pennsylvania from LaMont Medical in Madison, Wisconsin. Prior to that, he was at the Cleveland Clinic and before that the National Institutes of Health.

In his new role, he will lead RedPath's efforts in the design and development of a state-of-the-art laboratory.

(more)

“One of the things I look forward to is helping RedPath bring its vision to life by building a high-tech laboratory centered on RedPath’s customized laboratory information system,” said Jacobs. “This system will coordinate the complex processes of RedPath’s molecular analyses and transmit detailed diagnostic information to a growing customer base.”

About RedPath Integrated Pathology Inc.

RedPath Integrated Pathology, Inc. is a national specialty laboratory that provides complex cancer diagnostic testing for pathologists, oncologists and clinicians. Its patented molecular-based analysis, PathFinderTG®, integrates with routine pathology review of fixed slides, cytology and fluid specimens to render an early and definitive diagnosis where none would otherwise exist, improving patient outcomes and reducing healthcare costs. www.redpathip.com

.# # #